Human Abuse Potential of Single Oral Doses of Sunobinop, a Novel, Highly Potent, and Selective Partial Agonist for Nociceptin/Orphanin-FQ Peptide (NOP) Receptors
Drug-liking following sunobinop at a potential therapeutic dose was not different from placebo and was significantly lower compared with triazolam at a recommended dose. In addition, its good tolerability profile suggests sunobinop may be a useful new treatment option, particularly in at-risk populations.
Authors
- Manjunath S. Shet (ORCID: https://orcid.org/0000-0003-4192-785X)
- Glen Apseloff
- Garth T. Whiteside (ORCID: https://orcid.org/0000-0001-8128-0806)
- Alessandra Cipriano (ORCID: https://orcid.org/0000-0002-9062-5914)
- Stephen Harris (ORCID: https://orcid.org/0009-0006-8660-5597)
- Ellie He
- Kerri A. Schoedel
Institutions
- AIDS Clinical Trials Group (US)
- Stamford Hospital (US)
- Altrecht GGZ (NL)
Publication Details
- Journal
- Journal of Clinical Psychopharmacology
- Published
- 2026-03-23
- DOI
- https://doi.org/10.1097/jcp.0000000000002147
- Primary Topic
- Neuropeptides and Animal Physiology
- Type
- article
- Field-Weighted Citation Impact
- 0.00